Tepoditamab (MCLA-117) is a bispecific monoclonal antibody engineered to target CLEC12A on myeloid cells and CD3 on cytotoxic T cells. CLEC12A is recognized as a myeloid differentiation antigen. This antibody facilitates the targeted destruction of both acute myeloid leukemia (AML) progenitor and stem cells. It achieves this through the induction of T cell-mediated cytotoxicity, leading to the proliferative lysis of AML cells. Tepoditamab (MCLA-117) is particularly valuable for research focused on the mechanisms and therapeutic interventions of acute myeloid leukemia.
Tepoditamab (MCLA-117) is a bispecific monoclonal antibody engineered to target CLEC12A on myeloid cells and CD3 on cytotoxic T cells. CLEC12A is recognized as a myeloid differentiation antigen. This antibody facilitates the targeted destruction of both acute myeloid leukemia (AML) progenitor and stem cells. It achieves this through the induction of T cell-mediated cytotoxicity, leading to the proliferative lysis of AML cells. Tepoditamab (MCLA-117) is particularly valuable for research focused on the mechanisms and therapeutic interventions of acute myeloid leukemia.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
